• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

唐氏综合征患者的智力障碍程度与阿尔茨海默病发病时间的关系。

Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.

机构信息

Waisman Center, University of Wisconsin-Madison, Madison, WI, USA.

School of Human Ecology, University of Wisconsin-Madison, Madison, WI, USA.

出版信息

J Alzheimers Dis. 2023;95(1):213-225. doi: 10.3233/JAD-230200.

DOI:10.3233/JAD-230200
PMID:37482997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10578224/
Abstract

BACKGROUND

Trisomy 21 causes Down syndrome (DS) and is a recognized cause of early-onset Alzheimer's disease (AD).

OBJECTIVE

The current study sought to determine if premorbid intellectual disability level (ID) was associated with variability in age-trajectories of AD biomarkers and cognitive impairments. General linear mixed models compared the age-trajectory of the AD biomarkers PET Aβ and tau and cognitive decline across premorbid ID levels (mild, moderate, and severe/profound), in models controlling trisomy type, APOE status, biological sex, and site.

METHODS

Analyses involved adults with DS from the Alzheimer's Biomarkers Consortium-Down Syndrome. Participants completed measures of memory, mental status, and visuospatial ability. Premorbid ID level was based on IQ or mental age scores prior to dementia concerns. PET was acquired using [11C] PiB for Aβ, and [18F] AV-1451 for tau.

RESULTS

Cognitive data was available for 361 participants with a mean age of 45.22 (SD = 9.92) and PET biomarker data was available for 154 participants. There was not a significant effect of premorbid ID level by age on cognitive outcomes. There was not a significant effect of premorbid ID by age on PET Aβ or on tau PET. There was not a significant difference in age at time of study visit of those with mild cognitive impairment-DS or dementia by premorbid ID level.

CONCLUSION

Findings provide robust evidence of a similar time course in AD trajectory across premorbid ID levels, laying the groundwork for the inclusion of individuals with DS with a variety of IQ levels in clinical AD trials.

摘要

背景

21 三体综合征导致唐氏综合征(DS),是早发性阿尔茨海默病(AD)的公认病因。

目的

本研究旨在确定在 AD 生物标志物和认知障碍的年龄轨迹中,发病前智力障碍水平(ID)是否与变异性相关。在控制三体类型、APOE 状态、生物性别和地点的模型中,使用广义线性混合模型比较 AD 生物标志物 PET Aβ和tau以及认知衰退的年龄轨迹,在发病前 ID 水平(轻度、中度和重度/严重)之间进行比较。

方法

分析涉及来自阿尔茨海默病生物标志物联盟-唐氏综合征的 DS 成人。参与者完成了记忆、精神状态和空间视觉能力的测量。发病前 ID 水平基于痴呆前的智商或心理年龄得分。使用[11C]PiB 进行 Aβ的 PET 和[18F]AV-1451 进行 tau 的 PET。

结果

361 名参与者的认知数据可用,平均年龄为 45.22(SD=9.92),154 名参与者的 PET 生物标志物数据可用。发病前 ID 水平与年龄对认知结果没有显著影响。发病前 ID 水平与年龄对 PET Aβ或 tau PET 没有显著影响。根据发病前 ID 水平,轻度认知障碍-DS 或痴呆患者的研究就诊时的年龄没有显著差异。

结论

研究结果为发病前 ID 水平在 AD 轨迹中的相似时间过程提供了有力证据,为在 AD 临床试验中纳入各种智商水平的 DS 个体奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/1c214b7858c3/jad-95-jad230200-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/01be02a98112/jad-95-jad230200-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/35ccf219dd95/jad-95-jad230200-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/1c214b7858c3/jad-95-jad230200-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/01be02a98112/jad-95-jad230200-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/35ccf219dd95/jad-95-jad230200-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76af/10578224/1c214b7858c3/jad-95-jad230200-g003.jpg

相似文献

1
Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.唐氏综合征患者的智力障碍程度与阿尔茨海默病发病时间的关系。
J Alzheimers Dis. 2023;95(1):213-225. doi: 10.3233/JAD-230200.
2
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.淀粉样蛋白 PET 和 tau-PET 评估唐氏综合征患者症状性阿尔茨海默病的时间轴:一项纵向队列研究。
Lancet Neurol. 2024 Dec;23(12):1214-1224. doi: 10.1016/S1474-4422(24)00426-5.
3
Behavioral and psychological symptoms of dementia and Alzheimer's disease progression in Down syndrome.唐氏综合征中痴呆和阿尔茨海默病进展的行为和心理症状
J Neurodev Disord. 2025 Apr 11;17(1):19. doi: 10.1186/s11689-025-09604-w.
4
Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.唐氏综合征和临床前阿尔茨海默病中β-淀粉样蛋白和tau病理的联合空间关联:与早期认知障碍的横断面关联
Alzheimers Dement. 2025 Jul;21(7):e70424. doi: 10.1002/alz.70424.
5
Modified Cued Recall Test: Longitudinal Analysis of Test Versions and Item Recall in Adults With Down Syndrome.改良线索回忆测试:唐氏综合征成人患者测试版本及项目回忆的纵向分析
J Intellect Disabil Res. 2025 Apr 20. doi: 10.1111/jir.13237.
6
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.唐氏综合征与常染色体显性阿尔茨海默病患者淀粉样蛋白负担的比较:一项横断面研究。
Lancet Neurol. 2023 Jan;22(1):55-65. doi: 10.1016/S1474-4422(22)00408-2.
7
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study.利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau蛋白脑沉积及认知衰退:一项纵向队列研究。
Lancet Neurol. 2025 Jul;24(7):591-600. doi: 10.1016/S1474-4422(25)00158-9.
8
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta.载脂蛋白E4(APOE4)对可溶性和不溶性tau蛋白病理的影响主要受β-淀粉样蛋白的影响。
Brain. 2025 Jan 16. doi: 10.1093/brain/awaf016.
9
Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome.唐氏综合征中体重指数与阿尔茨海默病病理及症状学关系的纵向研究。
Alzheimers Dement. 2025 Jun;21(6):e70387. doi: 10.1002/alz.70387.
10
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.唐氏综合征与常染色体显性阿尔茨海默病患者 Tau 蛋白扩散的比较:一项横断面研究。
Lancet Neurol. 2024 May;23(5):500-510. doi: 10.1016/S1474-4422(24)00084-X.

引用本文的文献

1
Systematic review and evidence gap mapping of Alzheimer's disease biomarker studies in those with intellectual and developmental disability.智力和发育障碍者阿尔茨海默病生物标志物研究的系统评价与证据缺口图谱分析
Alzheimers Dement (Amst). 2025 Sep 1;17(3):e70175. doi: 10.1002/dad2.70175. eCollection 2025 Jul-Sep.
2
Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.唐氏综合征和临床前阿尔茨海默病中β-淀粉样蛋白和tau病理的联合空间关联:与早期认知障碍的横断面关联
Alzheimers Dement. 2025 Jul;21(7):e70424. doi: 10.1002/alz.70424.
3

本文引用的文献

1
Does Employment Complexity Promote Healthy Cognitive Aging in Down Syndrome?就业复杂性是否能促进唐氏综合征人群的健康认知老化?
J Intellect Disabil. 2024 Jun;28(2):499-513. doi: 10.1177/17446295231169379. Epub 2023 Apr 11.
2
A modified Cued Recall Test for detecting prodromal AD in adults with Down syndrome.一种用于检测唐氏综合征成人前驱期阿尔茨海默病的改良线索回忆测试。
Alzheimers Dement (Amst). 2022 Oct 3;14(1):e12361. doi: 10.1002/dad2.12361. eCollection 2022.
3
Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome.
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study.
利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau蛋白脑沉积及认知衰退:一项纵向队列研究。
Lancet Neurol. 2025 Jul;24(7):591-600. doi: 10.1016/S1474-4422(25)00158-9.
4
Resistance and resilience to Alzheimer's disease in Down syndrome.唐氏综合征对阿尔茨海默病的抵抗力和恢复力
Alzheimers Dement. 2025 Apr;21(4):e70151. doi: 10.1002/alz.70151.
5
Modified Cued Recall Test: Longitudinal Analysis of Test Versions and Item Recall in Adults With Down Syndrome.改良线索回忆测试:唐氏综合征成人患者测试版本及项目回忆的纵向分析
J Intellect Disabil Res. 2025 Apr 20. doi: 10.1111/jir.13237.
6
Characterization of white matter hyperintensities in Down syndrome.唐氏综合征患者脑白质高信号特征分析。
Alzheimers Dement. 2024 Sep;20(9):6527-6541. doi: 10.1002/alz.14146. Epub 2024 Aug 1.
7
Symptoms and age of prodromal Alzheimer's disease in Down syndrome: a systematic review and meta-analysis.唐氏综合征前驱期阿尔茨海默病的症状和发病年龄:系统评价和荟萃分析。
Neurol Sci. 2024 Jun;45(6):2445-2460. doi: 10.1007/s10072-023-07292-9. Epub 2024 Jan 16.
唐氏综合征患者阿尔茨海默病连续谱中的纵向临床和认知变化。
JAMA Netw Open. 2022 Aug 1;5(8):e2225573. doi: 10.1001/jamanetworkopen.2022.25573.
4
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.阿尔茨海默病与唐氏综合征患者预期寿命的关联。
JAMA Netw Open. 2022 May 2;5(5):e2212910. doi: 10.1001/jamanetworkopen.2022.12910.
5
Role of tau deposition in early cognitive decline in Down syndrome.tau蛋白沉积在唐氏综合征早期认知衰退中的作用。
Alzheimers Dement (Amst). 2022 Apr 1;14(1):e12256. doi: 10.1002/dad2.12256. eCollection 2022.
6
Alzheimer's disease associated with Down syndrome: a genetic form of dementia.唐氏综合征相关的阿尔茨海默病:一种遗传性痴呆。
Lancet Neurol. 2021 Nov;20(11):930-942. doi: 10.1016/S1474-4422(21)00245-3.
7
Cognitive Function during the Prodromal Stage of Alzheimer's Disease in Down Syndrome: Comparing Models.唐氏综合征患者阿尔茨海默病前驱期的认知功能:模型比较
Brain Sci. 2021 Sep 16;11(9):1220. doi: 10.3390/brainsci11091220.
8
Longitudinal assessment of dementia measures in Down syndrome.唐氏综合征痴呆测量的纵向评估
Alzheimers Dement (Amst). 2020 Nov 14;12(1):e12075. doi: 10.1002/dad2.12075. eCollection 2020.
9
Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome.唐氏综合征向阿尔茨海默病临床前期和前驱期转变的认知指标
Alzheimers Dement (Amst). 2020 Sep 13;12(1):e12096. doi: 10.1002/dad2.12096. eCollection 2020.
10
The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.阿尔茨海默病生物标志物联盟-唐氏综合征:原理与方法
Alzheimers Dement (Amst). 2020 Aug 3;12(1):e12065. doi: 10.1002/dad2.12065. eCollection 2020.